advertise

Tuesday, 4 November 2014

Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication.

To Brows a Full Report with Toc: http://www.researchmoz.us/non-hodgkin-lymphoma-therapeutics-in-major-developed-markets-to-2020-new-entrants-and-promising-pipeline-widen-targeted-and-immunotherapeutic-treatment-options-report.html

It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).

The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval) are expected to have a significant impact on the market size. Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period.

The emerging treatment challenges in the current treatment landscape (which include, treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the market is set to increase a modest pace due to the patent expiry of the gold-standard therapy during the forecast period.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. It includes:

    A brief introduction to NHL, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
    In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
    A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
    Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
    Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
    Discussion of the drivers of and barriers to market growth
    In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006


Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

    Understand the NHL pipeline and the factors that indicate that it is becoming more innovative
    Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
    Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
    Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the NHL market
    Accelerate and strengthen your market position by identifying key companies for strategic partnerships

All Repoers of this Category Here: http://www.researchmoz.us/therapeutic-area-market-reports-37.html


About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US: 


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/

No comments:

Post a Comment